康希諾(06185.HK):擁有新型冠狀病毒疫苗生產和商業化全部權利
康希諾生物(06185.HK)注意到股票價格波動及部份媒體有關重組新型冠狀病毒疫苗(腺病毒載體)「Ad5-nCoV」在貴州生產的報道。公司對此澄清,其擁有Ad5-nCoV的生產和商業化的全部權利;及疫苗生產者應具有足夠的生產疫苗的能力和資質,並受國家藥品監督管理局監管。
聯交所警示聲明,Ad5-nCoV的安全性及有效性須經臨床研究證實,暫無法保證公司將能最終成功開發或銷售Ad5-nCoV。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.